business

This Biotech Stock Plunges 54%. Its Sickle Cell Drug Has ‘No Viable Path Forward.’

Yahoo Finance · Jun 2, 2026, 4:13 PM · Also reported by 2 other sources

Read full story on Yahoo Finance → More top stories

Also covered by

Investing.com ADC Therapeutics stock plunges on trial safety concerns Investing.com Sleep Number stock plunges 60% on bankruptcy preparation report

Aggregated and edited by the Scoop newsroom. We surface news from Yahoo Finance alongside other reporting so you can compare coverage in one place. Editorial policy · Corrections · About Scoop

This Biotech Stock Plunges 54%. Its Sickle Cell Drug Has ‘No Viable Path Forward.’

Also covered by

More in business